|Immunocytochemistry (ICC)||20 ug/ml|
|Immunofluorescence (IF)||20 ug/ml|
|Immunohistochemistry (IHC)||2.5 ug/ml|
|Western Blot (WB)||0.5-1 ug/ml|
|Tested Species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A 15 amino acid peptide from near the carboxy terminus of human KAI1.|
|Purification||Antigen affinity chromatography|
|Contains||0.02% sodium azide|
|Storage conditions||Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
A suggested positive control is A549 cell lysate.
PA5-20356 can be used with blocking peptide PEP-0476.
KAI1 was initially identified from a T-cell activation study as a four-transmembrane protein that plays an accessory role in T-cell activation, and was later determined to act as a cancer metastasis suppressor gene. This protein is ubiquitously expressed at moderate to high levels in most tissues, but its expression is downregulated during tumor progression. The loss of KAI1 and p53 is associated with poor survival for prostate and other cancer patients. Recently, KAI1 was found to interact with DARC, the Duffy antigen for chemokines using a yeast two hybrid screen. It is thought that tumor cells dislodged from the primary tumor and expressing KAI1 interact with DARC proteins expressed on vascular cells, transmitting a senescent signal to the tumor cells, while tumor cells that have lost KAI1 expression can proliferate and potentially give rise to metastases. At least two isoforms of KAI1 are known to exist.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: 4F9; C33; C33 antigen; CD82; CD82 antigen; CD82 antigen (R2 leukocyte antigen antigen detected by monoclonal and antibody IA4)); CD82 antigen (R2 leukocyte antigen, antigen detected by monoclonal and antibody IA4)); GR15; IA4; Inducible membrane protein R2; KAI1; Kangai 1 (suppression of tumerigenicity 6 prostate) CD82 antigen; kangai 1 (suppression of tumorigenicity 6), prostate; kangai 1 (suppression of tumorigenicity 6, prostate); Kangai 1 (suppression of tumorigenicity 6, prostate; CD82 antigen (R2 leukocyte antigen, antigen detected by monoclonal and antibody IA4)); Metastasis suppressor Kangai-1; Metastasis suppressor Kangai-1 homolog; R2; SAR2; ST6; Suppressor of tumorigenicity 6 protein; Tetraspanin-27; Tspan-27; TSPAN27
Gene Aliases: 4F9; AA682076; AL023070; C33; CD82; GR15; IA4; KAI1; R2; SAR2; ST6; TSPAN27
If an Invitrogen™ antibody doesn’t perform as described on our website or datasheet, we’ll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.